Pain is reduced by transcutaneous cervical vagus nerve stimulation and correlated with cardiorespiratory variability measures in the context of opioid withdrawal

Asim H. Gazi, Anna B. Harrison, Tamara P. Lambert, Afra Nawar, Malik Obideen, Emily Driggers, Viola Vaccarino, Amit Shah, Christopher J. Rozell, Marom Bikson, Justine W. Welsh, Omer T. Inan, J. Douglas BremnerFrontiers in Pain Research 2022 · DOI

TL;DR

This pilot study demonstrates that transcutaneous cervical vagus nerve stimulation (tcVNS) can effectively reduce pain experienced during acute opioid withdrawal. Furthermore, it establishes a novel correlation between changes in pain and objective cardiorespiratory measures like respiration pattern variability (RPV) and heart rate variability (HRV), suggesting potential for non-pharmacological pain management and monitoring in this population.

What Problem Does This Paper Address?

The opioid epidemic continues to be a major public health crisis, with opioid use disorder (OUD) contributing to a significant number of overdose deaths. A major hurdle in OUD recovery is managing the intense pain associated with opioid withdrawal, which can be a significant barrier to treatment adherence. Current treatment options for OUD, such as medication-assisted treatment, face accessibility issues, and the detoxification period can be particularly challenging due to withdrawal-induced hyperalgesia. This paper addresses the need for effective, non-pharmacological interventions to manage pain during acute opioid withdrawal and explores objective physiological markers that could aid in monitoring and managing this pain.

Methods

The study employed a randomized, double-blind, sham-controlled design with 20 patients undergoing acute opioid withdrawal. Participants were randomly assigned to receive either active tcVNS or sham stimulation for a two-hour in-lab protocol. This protocol included opioid cue audio and videos designed to elicit craving, interspersed with neutral control stimuli.

Key measurements included:

  • Pain Assessment: The Numerical Rating Scale (NRS Pain) was used to assess pain levels at the beginning and end of the protocol.
  • Cardiorespiratory Monitoring: Electrocardiogram (ECG) and respiratory effort (RSP) signals were recorded throughout the protocol.
  • Feature Extraction: From the physiological signals, Heart Rate Variability (HRV) metrics (SDNN and RMSSD) and Respiration Pattern Variability (RPV) metrics (CV(Tᵢ), CV(Tₑ), and CV(RR)) were extracted.

The primary analysis focused on the change in NRS Pain scores (Δ NRS Pain) between the pre- and post-protocol measurements. Correlations between Δ NRS Pain and changes in HRV and RPV (Δ HRV, Δ RPV) were investigated using Spearman correlations. Statistical adjustments were performed to account for device group and other potential confounders.

Datasets

Not discussed in the paper. The study involved data collected from 20 participants.

Key Insights and Ideas

  • tcVNS as a Pain Reducer in Opioid Withdrawal: The study provides the first direct evidence that tcVNS can significantly reduce pain in individuals experiencing acute opioid withdrawal. This is a crucial finding given the challenges in managing withdrawal pain.
  • Breathing Irregularity as a Pain Correlate: The discovery of a positive correlation between changes in respiration pattern variability (RPV) and changes in pain is novel. This suggests that disruptions in breathing patterns might be a physiological indicator or contributor to pain during withdrawal.
  • HRV as a Pain Correlate: The study reinforces previous findings by showing a negative correlation between changes in heart rate variability (HRV) and pain. This aligns with the broader understanding that dysregulated autonomic function, reflected in HRV, is often associated with chronic pain states.
  • Potential for Objective Monitoring: The correlation between pain and objective cardiorespiratory measures opens avenues for developing wearable sensors to monitor pain non-invasively, which is particularly valuable for patients with OUD who may have compromised subjective reporting during withdrawal.
  • Independent Pathways: Statistical adjustments suggest that the effects of tcVNS on pain and the relationships between pain and cardiorespiratory measures might operate through distinct pathways, implying that physiological monitoring could be effective even without stimulation.

Key Results

  • Patients receiving active tcVNS showed a statistically significant reduction in pain scores (Δ NRS Pain: -0.8 ± 2.4) compared to the sham group (Δ NRS Pain: 0.9 ± 1.0) (P = 0.045).
  • A significant positive correlation was found between changes in pain (Δ NRS Pain) and changes in respiration pattern variability, specifically the coefficient of variation of inspiration time (Δ CV(Tᵢ)) (Spearman's ρ = 0.46, P = 0.04).
  • Following adjustment for device group, a significant negative correlation was detected between changes in pain (Δ NRS Pain) and changes in heart rate variability, specifically the standard deviation of NN intervals (Δ SDNN) (Spearman's ρ = -0.43, P = 0.04).
  • The reduction in pain with active tcVNS remained statistically significant even after adjusting for cardiorespiratory variability measures.

Limitations and Future Work

  • Small Sample Size: The study acknowledges its small sample size, which limits statistical power and increases the margin of error. Larger studies with adequate statistical power are needed.
  • Single Timepoint Measurement: Pain was only measured at the beginning and end of the protocol, precluding analysis of temporal trends. Future research should incorporate multiple pain measurements.
  • NRS Pain Limitations: The NRS Pain scale provides a single numerical response and may not capture the multifaceted nature of pain. Future studies could use more comprehensive pain assessments like the McGill Pain Questionnaire.
  • Right vs. Left tcVNS: The study only investigated right-sided tcVNS, and future research should explore potential differences with left-sided stimulation.
  • Blinding Verification: The study did not statistically test the effectiveness of the blinding procedure for researchers and patients.
  • Generalizability: The findings are from a pilot study and may not generalize to outpatient settings or longer periods of opioid withdrawal.

Future work should focus on larger, adequately powered studies, exploring adjunctive tcVNS with standard care, validating the pain-RPV correlation, investigating the specific role of inspiratory RPV, and evaluating the potential of wearable sensors for remote monitoring and management of pain in OUD patients.

Summary updated

Abstract

Over 100,000 individuals in the United States lost their lives secondary to drug overdose in 2021, with opioid use disorder (OUD) being a leading cause. Pain is an important component of opioid withdrawal, which can complicate recovery from OUD. This study's objectives were to assess the effects of transcutaneous cervical vagus nerve stimulation (tcVNS), a technique shown to reduce sympathetic arousal in other populations, on pain during acute opioid withdrawal and to study pain's relationships with objective cardiorespiratory markers. Twenty patients with OUD underwent opioid withdrawal while participating in a two-hour protocol. The protocol involved opioid cues to induce opioid craving and neutral conditions for control purposes. Adhering to a double-blind design, patients were randomly assigned to receive active tcVNS (<i>n</i> = 9) or sham stimulation (<i>n</i> = 11) throughout the protocol. At the beginning and end of the protocol, patients' pain levels were assessed using the numerical rating scale (0-10 scale) for pain (NRS Pain). During the protocol, electrocardiogram and respiratory effort signals were measured, from which heart rate variability (HRV) and respiration pattern variability (RPV) were extracted. Pre- to post- changes (denoted with a Δ) were computed for all measures. Δ NRS Pain scores were lower (<i>P</i> = 0.045) for the active group (mean ± standard deviation: -0.8 ± 2.4) compared to the sham group (0.9 ± 1.0). A positive correlation existed between Δ NRS pain scores and Δ RPV (Spearman's <i>ρ</i> = 0.46; <i>P</i> = 0.04). Following adjustment for device group, a negative correlation existed between Δ HRV and Δ NRS Pain (Spearman's <i>ρ</i> = -0.43; <i>P</i> = 0.04). This randomized, double-blind, sham-controlled pilot study provides the first evidence of tcVNS-induced reductions in pain in patients with OUD experiencing opioid withdrawal. This study also provides the first quantitative evidence of an association between breathing irregularity and pain. The correlations between changes in pain and changes in objective physiological markers add validity to the data. Given the clinical importance of reducing pain non-pharmacologically, the findings support the need for further investigation of tcVNS and wearable cardiorespiratory sensing for pain monitoring and management in patients with OUD.
BibTeX
@inproceedings{gazi2022pain,
  author = {Asim H. Gazi and Anna B. Harrison and Tamara P. Lambert and Afra Nawar and Malik Obideen and Emily Driggers and Viola Vaccarino and Amit Shah and Christopher J. Rozell and Marom Bikson and Justine W. Welsh and Omer T. Inan and J. Douglas Bremner},
  title = {{Pain is reduced by transcutaneous cervical vagus nerve stimulation and correlated with cardiorespiratory variability measures in the context of opioid withdrawal}},
  booktitle = {Frontiers in Pain Research},
  year = {2022},
  doi = {10.3389/fpain.2022.1031368},
}
Figure